Literature DB >> 18689805

Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney.

Alicja Bukowska1, Uwe Lendeckel, Alexander Krohn, Gerburg Keilhoff, Sara ten Have, Klaus Hinrich Neumann, Andreas Goette.   

Abstract

AIMS: Recent studies suggest that atrial fibrillation (AF) substantially influences microvascular flow in ventricular myocardium. This process may contribute to the occurrence of heart failure in AF. In general, development of heart failure and renal dysfunction go hand-in-hand causing systemic fluid overload and oedema. So far, it is unknown whether AF itself influences renal function. The aim of the present study was to determine the impact of AF on renal gene expression in a closed chest rapid atrial pacing model. METHODS AND
RESULTS: A total of 14 pigs were studied. In five pigs, rapid atrial pacing (AT) was performed for 7 h (600 bpm); in five additional animals, rapid atrial pacing was performed in the presence of irbesartan infusion (irbesartan group). Four pigs were instrumented without interventions (sham). After the pacing period, renal expression of collagen I alpha 1 and I alpha 3, transforming growth factor-beta (TGF-beta), neutral endopeptidase (NEP; the main enzyme involved in natriuretic protein metabolism), and atrial natriuretic peptide (ANP) were determined by RT-PCR and immunoblot analysis. Functional in vitro experiments were performed using HEK-293 kidney cells. Renal mRNA expression of NEP was substantially down-regulated during AT (AT: 12.7 +/- 9.3% vs. sham: 100 +/- 43.4%; P < 0.01). Results at the mRNA level were confirmed at the protein level. Irbesartan therapy did not prevent down-regulation of NEP. In contrast, TGF-beta1 mRNA expression was up-regulated (AT: 208.5 +/- 79.3% vs. sham: 100 +/- 34.6% P< 0.05). Collagen and angiotensin II type 1 receptor (AT1R) expression were not significantly altered by AT. HEK-293 cells were used to determine the potential humoral factors involved in down-regulation of NEP. Application of aldosterone, ANP, asymmetric dimethylarginine, and angiotensin peptides failed to cause down-regulation of renal NEP expression in vitro.
CONCLUSION: AT reduces NEP expression and stimulates TGF-beta1 signalling in the kidneys. Thus, even brief episodes of AT affect renal gene expression, which may account for structural renal changes and alterations of renal function in the long term.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18689805     DOI: 10.1093/europace/eun206

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  10 in total

Review 1.  Proteomics and transcriptomics in atrial fibrillation.

Authors:  Marc Sühling; Carmen Wolke; Christian Scharf; Uwe Lendeckel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-01-09

2.  Antithrombotic therapy after coronary artery stenting in atrial fibrillation: dual therapy encompassing NOAC plus P2Y12 inhibitor is ready for prime time!

Authors:  Andreas Goette
Journal:  Ann Transl Med       Date:  2019-12

3.  Under-recognized post-stroke acute kidney injury: risk factors and relevance for stroke outcome of a frequent comorbidity.

Authors:  Fabrizio Grosjean; Michela Tonani; Rosario Maccarrone; Carlo Cerra; Federica Spaltini; Annalisa De Silvestri; Francesco Falaschi; Simona Migliazza; Carmine Tinelli; Teresa Rampino; Antonio Di Sabatino; Alessandra Martignoni
Journal:  Int Urol Nephrol       Date:  2019-06-20       Impact factor: 2.370

4.  Acute kidney injury without need for dialysis, incidence, its impact on long-term stroke survival and progression to chronic kidney disease.

Authors:  Shrikant D Pande; Debajyoti Roy; Aye Aye Khine; May M Win; Lorecar Lolong; Ni Thu Shan; Pei Ting Tan; Tian Ming Tu
Journal:  BMJ Open       Date:  2022-05-25       Impact factor: 3.006

5.  A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation.

Authors:  Deborah M Dickey; Andrea R Yoder; Lincoln R Potter
Journal:  J Biol Chem       Date:  2009-05-19       Impact factor: 5.157

6.  Atrial Fibrillation and Risk of ESRD in Adults with CKD.

Authors:  Nisha Bansal; Dawei Xie; Kelvin Tao; Jing Chen; Rajat Deo; Edward Horwitz; Chi-Yuan Hsu; Radha Krishna Kallem; Martin G Keane; Claudia M Lora; Dominic Raj; Elsayed Z Soliman; Louise Strauss; Myles Wolf; Alan S Go
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-12       Impact factor: 8.237

Review 7.  WNT signaling in atrial fibrillation.

Authors:  Carmen Wolke; Elmer Antileo; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-27

8.  Effects of Prevalent and Incident Atrial Fibrillation on Renal Outcome, Cardiovascular Events, and Mortality in Patients with Chronic Kidney Disease.

Authors:  Hsin-Hui Hsu; Chew-Teng Kor; Yao-Peng Hsieh; Ping-Fang Chiu
Journal:  J Clin Med       Date:  2019-09-03       Impact factor: 4.241

Review 9.  Atrial Fibrillation, thromboembolic risk, and the potential role of the natriuretic peptides, a focus on BNP and NT-proBNP - A narrative review.

Authors:  Brian Kerr; Lisa Brandon
Journal:  Int J Cardiol Heart Vasc       Date:  2022-10-10

10.  Anticoagulation Stability Depends on CHADS2 Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation.

Authors:  Keita Odashiro; Taku Yokoyama; Mitsuhiro Fukata; Takeshi Arita; Toru Maruyama; Koichi Akashi
Journal:  J Atheroscler Thromb       Date:  2016-06-16       Impact factor: 4.928

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.